87 related articles for article (PubMed ID: 22897844)
1. Burkitt lymphoma: much more than MYC.
Dominguez-Sola D; Dalla-Favera R
Cancer Cell; 2012 Aug; 22(2):141-2. PubMed ID: 22897844
[TBL] [Abstract][Full Text] [Related]
2. Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells.
Sander S; Rajewsky K
Oncotarget; 2012 Oct; 3(10):1066-7. PubMed ID: 23164662
[No Abstract] [Full Text] [Related]
3. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
4. Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma.
Granato M; Rizzello C; Romeo MA; Yadav S; Santarelli R; D'Orazi G; Faggioni A; Cirone M
Int J Biochem Cell Biol; 2016 Oct; 79():393-400. PubMed ID: 27620077
[TBL] [Abstract][Full Text] [Related]
5. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.
Yoon JW; Gallant M; Lamm ML; Iannaccone S; Vieux KF; Proytcheva M; Hyjek E; Iannaccone P; Walterhouse D
Mol Cancer Res; 2013 Jun; 11(6):604-15. PubMed ID: 23525267
[TBL] [Abstract][Full Text] [Related]
6. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.
Vettraino M; Manerba M; Govoni M; Di Stefano G
Anticancer Drugs; 2013 Sep; 24(8):862-70. PubMed ID: 23797802
[TBL] [Abstract][Full Text] [Related]
7. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
[TBL] [Abstract][Full Text] [Related]
9. Impact of MYC on malignant behavior.
Ott G
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):100-6. PubMed ID: 25696841
[TBL] [Abstract][Full Text] [Related]
10. Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Yang Z; Shah K; Busby T; Giles K; Khodadadi-Jamayran A; Li W; Jiang H
J Clin Invest; 2018 Aug; 128(8):3605-3618. PubMed ID: 29870403
[TBL] [Abstract][Full Text] [Related]
11. Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma.
Meznarich J; Miles R; Paxton CN; Afify Z
Pediatr Blood Cancer; 2016 May; 63(5):938-40. PubMed ID: 26785246
[TBL] [Abstract][Full Text] [Related]
12. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
13. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.
Hatakeyama S; Watanabe M; Fujii Y; Nakayama KI
Cancer Res; 2005 Sep; 65(17):7874-9. PubMed ID: 16140957
[TBL] [Abstract][Full Text] [Related]
14. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
15. Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.
De Falco G; Ambrosio MR; Fuligni F; Onnis A; Bellan C; Rocca BJ; Navari M; Etebari M; Mundo L; Gazaneo S; Facchetti F; Pileri SA; Leoncini L; Piccaluga PP
BMC Cancer; 2015 Oct; 15():668. PubMed ID: 26453442
[TBL] [Abstract][Full Text] [Related]
16. B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis.
Ruddell A; Mezquita P; Brandvold KA; Farr A; Iritani BM
Am J Pathol; 2003 Dec; 163(6):2233-45. PubMed ID: 14633598
[TBL] [Abstract][Full Text] [Related]
17. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
19. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
20. Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.
Turakhia SK; Hill BT; Dufresne SD; Nakashima MO; Cotta CV
Am J Clin Pathol; 2014 Sep; 142(3):339-46. PubMed ID: 25125624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
